Outcome Heterogeneity in Coronavirus Disease 2019 (COVID-19) Patients Receiving Tocilizumab.

Niu, Man Man; Cao, Yue; Li, Rui Xue; Fan, Guo Zhen; Hu, Peng

Niu, Man Man; Cao, Yue; Li, Rui Xue; Fan, Guo Zhen; Hu, Peng.

Afiliación

Niu MM; Department of Pediatrics, the First Affiliated Hospital of Anhui Medical University, Hefei, China.
Cao Y; Department of Pediatrics, the First Affiliated Hospital of Anhui Medical University, Hefei, China.
Li RX; Department of Pediatrics, the First Affiliated Hospital of Anhui Medical University, Hefei, China.
Fan GZ; Department of Pediatrics, the First Affiliated Hospital of Anhui Medical University, Hefei, China.
Hu P; Department of Pediatrics, the First Affiliated Hospital of Anhui Medical University, Hefei, China.

Clin Infect Dis ; 74(8): 1504, 2022 04 28.

Article en En | MEDLINE | ID: mdl-34534286

Asunto(s)

Tratamiento Farmacológico de COVID-19; Anticuerpos Monoclonales Humanizados/uso terapéutico; Humanos; SARS-CoV-2; Resultado del Tratamiento

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Tratamiento Farmacológico de COVID-19 Límite: Humans Idioma: En Revista: Clin Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google